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Summary. Mutations in the p53 tumor suppressor gene 
are the most common genetic alterations in human 
cancers. These mutations usually lead to strongly 
enhanced protein stabilization and allow detection by 
immunohistochemistry. Two monoclonal (DO-7 and 
PAb-240) and two polyclonal (Ab-7 and CM-1) 
antibodies were evaluated by standard immuno- 
peroxidase method in domestic animal tumors, chiefly 
squamous cell carcinomas (SCC), and osteosarcomas as 
positive controls. Immunoreactivity was detected in SCC 
of cattle, sheep, horse and cat as well as in feline actinic 
keratosis, with PAb-240 and CM-1 antibodies. One 
polyclonal antibody (Ab-7) did not give positive result at 
all, whereas DO-7 monoclonal antibody did not react in 
dogs and cats. Immunodetection of p53 protein is thus 
possible in al1 domestic species tested, especially with 
CM-1 and PAb-240 antibodies, and p53 alterations seem 
to occur early in carcinogenesis of feline SCC as in 
comparable human lesions. 
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lntroduction 
Nuclear p53 phosphoprotein referred to as "the 
guardian of the genome", is induced in response to DNA 
damage and acts as a transcriptional factor of cell cycle 
regulating proteins leading to either cell cycle arrest 
(especially in G 1  phase) or  apoptosis (Lee and 
Bernstein, 1995; Martin, 1995). p53 inactivation can 
result from genetic alteration (by deletion, point 
mutation or rearrangement) or from interaction with 
vira1 or cellular proteins (Levine et al., 1991; Momand et 
al., 1992; Milner, 1994; Kastan et al., 1995). p53 
inactivation consequently leads to the loss of p53 tumor- 
suppressive function, with increasing cell proliferation 
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and apoptosis inhibition. 
Comparison of p53 proteins from various species 
leads to identification of five domains highly conserved 
during evolution (Mayr et al., 1993, 1995; Okuda et al., 
1993; Pazzi et al., 1996; Veldhoen and Milner, 1998). 
Four of these five domains are found in the core region 
while block 1 is located on the amino-terminal region. 
Analysed p53 mutations in human neoplasia (Hollstein 
et al., 1991) and in few animal tumors (Mayr et al., 
1994, 1997; Zhuang et al., 1997; Johnson et al., 1998) 
are essentially clustered in DNA binding regions 
encoded by exons 5-9 and colocalized with highly 
conserved domains 11 to V. 
The leve1 of wild-type p53 protein in normal cells is 
undetectable by immunohistochemical staining due to 
the short life of the protein (20-30 minutes) (Ozbun and 
Butel, 1997). On the other hand, point mutations leading 
to aminoacid substitutions and to p53 stabilization, 
prolong its half-life up to 2 hours, allowing the 
accumulated mutant p53 to be detected by immuno- 
histochemistry (Martin, 1995). 
Imunohistochemical studies of p53 protein in 
domestic animals are now growing. p53 immuno- 
reactivity has been documented in squamous cell 
carcinomas (SCCs) in mammals (dog, cat, horse and 
cattle) (Johnston et al., 1996; Teifke and Lohr, 1996), in 
colorectal tumors (Fante et al., 1996; Gamblin et al., 
1997; Wolf et al., 1997), testicular tumors (Vitellozzi et 
al., 1998) and in canine osteosarcomas, with high 
prevalence in this tumor (Sagartz et al., 1996). The 
purpose of the study was to evaluate p53 immuno- 
reactivity in domestic species (especially on SCC), using 
four anti human p53 antibodies, and hence to define a 
simple immunohistochemical method appropriate for al1 
these species. 
Materials and methods 
Tumor material 
The investigations were carried out on 25 tumor 
tissues collected from various animal species (canine, 
feline, ovine, equine and bovine). The criteria for 
lmmunohistochemical expression of p53 in animal tumors 
including tumors in the study were based on: 1) the type 
of the tumor: SCC, colorectal adenocarcinomas or 
osteosarcomas, 2) the presence of previous data which 
notified the possibility to immunohistochemically detect 
p53 according to the type of cancer and to the chosen 
animal species. 
Al1 the tumors came from the Pathology Department 
of the National Veterinary School of Toulouse between 
1993 and 1998. Ten canine tumors were selected: three 
squamous cell carcinomas (one from the nasal cavities, 
one from the eyelid and one from digital extremity) and 
two actinic keratosis which is  considered a s  a 
precancerous lesion, two colorectal papillar adeno- 
carcinomas and three osteosarcomas (involving the 
appendicular skeleton). The  feline tumors were 
squamous cell carcinomas from the oral cavity (n=3), 
one from the eyelid (n=l) and five from the pinna (n=5) 
including two actinic keratosis. The equine squamous 
cell carcinomas, were of gastric (n=l), vulvar (n=l), and 
eyelid (n=l) origin. The bovine and ovine SCCs (one 
case each) were respectively tumors of the lower jaw and 
of the eyelid. Al1 cases were either necropsy specimens 
(immediately fixed after death) or surgical and biopsy 
specimens. 2-3 pm-thick sections of formalin-fixed (24 
to 48 hours) and paraffin-embedded tissues were preared 
and mounted on Superfrost+ slides (LLR3 plus, CML, 
France). A prerequisite hematoxylin and eosin staining 
confirmed histological features to verify adequate tumor 
sampling. 
microwave oven at 700W. Endogenous peroxidase was 
blocked by incubation in 0.9% H202 in PBS for five 
minutes at room temperature. To block non-specific 
binding sites of the antibodies, slides were washed for 
five minutes with PBS including 0.01% Tween 20 
(p7949, Sigma, France) and 0.01% non fat milk, and 
then incubated in 20% normal goat serum diluted in PBS 
containing 1% bovine serum albumin (BSA) for 20 
minutes at room temperature. Subsequently, the slides 
were incubated with primary anti p53 antibodies diluted 
in PBS including 1% BSA for 30  to 70  minutes, 
according to the chosen antibody, at room temperature 
except for  CM-1 primary antibody. In this case, 
incubation was performed overnight. The origin of 
primary antibodies as well as their characteristics are 
listed in table 1. The four antibodies tested consisted of 
two polyclonal antibodies i.e. Ab-7 and CM-1, and two 
monoclonal antibodies i.e. PAb-240 and DO-7, which 
recognize mutant p53 and both wild-type and mutant 
p53 respectively (Fig. 1). After washing (with PBS 
including tween 20 and non fat milk four times 5 
minutes each), sections were incubated for thirty minutes 
with biotinylated goat anti-rabbit antibody (for CM-1 
Immunohistochemistry 
Immunohistochemical analyses were performed by 
an avidin-biotin peroxidase technique. 2-3 pm sections 
from paraffin-embedded tissues were air-dried overnight 
at 56 OC, deparaffinized and rehydrated using toluene 
and acetone. After rinsing with water, the slides were 
treated with 0.1% trypsin (Merck, France) in phosphate 
buffered saline (PBS, pH 7.6), at 37 OC for 6 minutes 
only when CM-1 antibody was used as primary anti p53 
antibody. Enhancing antigen retrieval was established by 
boiling the slides for ten minutes, then two times for five 
minutes in 10 mM citrate buffer, pH 6, using a standard 
Table 1. Antibodies used for p53 immunohistochemistry. 
ANTlBODlES TYPE ORlGlN 
(isotype for monoclonal 
antibodies) 
DO-7 Monoclonal (lg G2bk) Mouse 
(M 7001, DAKO, France) 
Ab-7 Polyclonal Sheep 
(PC 35, kit Genzyme, France) 
CM-1 Polyclonal Rabbit 
(NCL-p53 CM-1, TEBU, France) 
PAb 240 Monoclonal Mouse 
(MCA 909, Realef, France) (lg (31) 
A 
PAb 240 
(2 10-226) 
CM- 1 ,  Ab-7 
@olyolonal antibodiss) 
1 -+ V : highly conierved domains of pS3 protcin 
1 -+ 393 : amino acid sequcncc of p53 proteh. 
Fig. 1. Diagram of the reported binding sites of the antibodies used for 
immunohistochemistry. 
SPEClFlClTY AND REACTIVITY* DlLUTlON INCUBATION 
WT and mutant p53 (tested in 
human) 
WT and mutant p53 (tested in 
human, mouse, rat) 
WT and mutant p53 (tested in 
dog) 
Mutant p53 (tested in dog, cat, 
cattle, horse) 
1 :50 30 min at room 
temperature 
1 :500 40 min at room 
temperature 
1:lOOO 16 hours at 4°C 
and 1 :2000 
1 :50 70 min at room 
temperature 
* : species for which antibody reactivity is known is precised in brackets. 
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antibody) or biotinylated goat anti-mouse antibody (for 
DO-7 and PAb 240 antibodies) diluted 1:100 in PBS 
including 1% BSA. When the primary anti p53 antibody 
tested was Ab-7, the secondary antibody used was a 
biotinylated rabbit anti-sheep antibody. After washing 
twice in PBS, the immune complexes were detected by 
the streptavidin-biotin horseradish peroxidase complex 
using 3,3'-diaminobenzidine (DAB) as chromogen 
according to the manufacturer7s instructions (ABC, 
Dako). To visualize bound antibodies, sections were 
covered with 0.6 pg/pl DAB in PBS ; to which 0.0012% 
of H202 was added, for several minutes. Slides were 
counterstained with Harris' haematoxylin, dehydrated 
and coverslipped. 
Two negative control sections for each case were 
treated as described above, except that primary antibody 
was omitted during the procedure (first negative control), 
or replaced by normal rabbit serum for  anti-p53 
polyclonal antibodies or the same isotype antibody for 
anti-p53 monoclonal antibodies (second negative 
control). 
Positive control slides consisted of paraffin sections 
from tissues known to be positive for p53 (human tumor 
pannel and canine osteosarcomas). Nonneoplastic tissue 
from each slide was used for interna1 control. 
Scoring of positive p53 immunoreactivity 
Specific nuclear immunoreactivity for p53 protein 
was scored semi-quantitatively on a graded scale from O 
to 3 for both intensity of staining (low: +, mild: ++, 
moderate: +++, marked: ++++ or intense: +++++) and 
its extent. This latter was evaluated as the percentage of 
positively stained tumor cells of the total number of 
tumor cells, in ten adjacent fields at a magnification of 
x400: O signifying no ceii staining, + indicating that less 
than 10% of tumor cells were positive, ++ indicating that 
10-50% of tumor cells were positive, and +++ signifying 
that more than 50% of tumor cells were positive. 
Background and cytoplasmic staining were recorded but 
were not incorporated into the scoring system. 
Results 
lmmunohistochemical expression of p53 in animal 
tumors 
Nuclear p53 staining was granular and relatively 
homogeneous and excluded nucleoli. The intensity of 
staining was mild to intense, particularly in positive 
controls. For positive control slides (human tumors or 
osteosarcomas), the extent of staining was evaluated at 
+++ irrespective of the anti-p53 antibody used, except 
for Ab-7 which did not label osteosarcomas. 
Nuclear p53 staining was absent in negative controls 
or  in adjacent nonneoplastic tissue. Nevertheless, 
cytoplasmic staining, occasionally marked, was almost 
systematically found in neoplastic keratinocytes, 
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chondrocytes or enterocytes, and was scarcely obsewed 
in osteoblasts and giant cells of osteosarcomas. This 
staining pattern was probably not specific for p53 
accumulation because it was also obtained in negative 
control slides incubated with normal serum, especially 
with rabbit serum, instead of polyclonal primary 
antibody. Besides, this nonspecific staining was more 
pronounced with polyclonal CM-1 antibody. 
Staining with Ab-7 antí-p53 antibody was completely 
absent, whatever species, except in human positive 
controls 
In canine and feline tumors including 
osteosarcomas, DO-7 antibody was unable to detect p53 
immunoreactivity. Nonspecific cytoplasmic p53 staining 
was only obtained and was mild to moderate. On the 
other hand, p53 immunoreactivity, i.e. specific nuclear 
staining, was detected using PAb-240 antibody in four 
tumors (osteosarcomas and one colorectal adeno- 
carcinoma) out of ten in the dog, and in seven tumors 
(including the two actinic keratosis) out of nine in the cat 
(Fig. 2). Results were similar with CM-1 antibody (Figs. 
3, 4). In dogs, none of the SCC tested in this study 
showed specific reactivity with any of the antibodies 
used. Tumors especially stained with PAb-240 were also 
positive for  CM-1 immunostaining (cf. table 2). 
However, extent of staining, i.e. the number of positive 
cells was higher with CM-1, in al1 tumors: the 
percentage of positive cells was often greater than 50% 
with CM-lantibody whereas the score was lower with 
PAb-240 antibody. Similarly, staining intensity was 
generally moderate with PAb 240 antibody whereas it 
was always marked to intense with CM-1 antibody. 
In other species, the results showed that ovine and 
bovine (Fig. 5) tumors revealed p53 immunoreactivity 
with CM-1, PAb 240 and DO-7 antibodies. Extent of 
staining was highest with CM-1, and was quite similar 
using PAb 240 or DO-7 antibodies. %o equine SCC 
(Fig. 6) showed intense nuclear staining in a majority of 
cells whatever the antibody used (more than 50% of cells 
were positive), whereas the third tumor was only slightly 
stained with DO-7 antibody. For these three species, 
intensity of p53 staining was moderate (PAb 240 
antibody) to marked (DO-7 and CM-1 antibodies) in 
s c c s .  
Discussion 
In this study, p53 immunohistochemistry was 
performed in severa1 domestic species by a standard 
peroxidase method using four antibodies: two 
monoclonal (DO-7 and PAb-240) and two polyclonal 
(CM-1 and Ab-7). p53 staining was evaluated on the 
same tumor type i.e. SCCs. In dogs, a few colorectal 
tumors and osteosarcomas were also analysed. 
Osteosarcomas were used as positive control as previous 
data showed marked immunoreactivity for this neoplasm 
lmmunohistochemical expression of p53 in animal tumors 
(Sagartz et al., 1996). We showed here that p53 nuclear 
protein could be detected by antibodies toward human 
protein in domestic animal species (i.e. canine, feline, 
equine, bovine and ovine). Nuclear p53 staining was 
specifically observed using CM-1 and PAb-240 
antibodies in dogs and cats, whereas p53-positive 
staining was also obtained with DO-7 antibody in the 
other species. Furthermore, p53 accumulation was 
generally detected in SCC from cats, horses and 
ruminants (although the case number was low), but not 
in SCC from dogs. 
No p53 staining was obsewed with polyclonal Ab-7 
antibody in any cases analysed. Severa1 reasons could 
explain this defect. First, this antibody may not 
recognize p53 protein in animal species except in rat and 
mouse. We have not found any data about Ab-7 
reactivity in animals except those provided by the 
manufacturer (Table 1). Second, the particular epitope 
denaturation by unmasking methods, or on the contrary, 
residual masked epitopes might not react with Ab-7 
antibody, preventing p53 staining. Third, technical 
problems such as antibody alterations (during transport 
for instance) should not be excluded. 
DO-7 antibody was not able to detect p53 
immunoreactivity in canine and feline tumors, whereas 
this antibody recognized ovine, equine or bovine p53 
proteins. Perhaps due to canine p53 stereospecificity, 
DO-7 antibody seems not to be as efficient as other 
antibodies to recognize p53 protein in dogs and cats. 
Whatever species tested, results were similar for 
PAb-240 and CM-1 antibodies. Nevertheless, staining 
intensity, as well as nonspecific and background 
staining, was more pronounced with CM-1. Consistent 
with this fact, presence of an appropriate negative 
control (same isotype or normal rabbit serum, instead of 
anti p53 primary antibody) was absolutely necessary in 
order to correctly interpret p53 staining. Consequently, 
staining was considered as nonspecific when it was 
equally present on the negative control as cytoplasmic 
staining, which is reported in some SCC lines (Caamano 
et al., 1993), various human cancers (Bosari et al., 1994; 
Faille et al., 1994; Flamini et al., 1996; Runnebaum et 
Table 2. Comparison of results of p53 immunostaining using PAb 240 and CM-1 antibodies. 
SPECIES AND CASE PERCENTAGE OF POSITIVE CELLS INTENSITY 
CM-1 PAh 240 CM-1 PAb 240 
Dog 
squamous cell carcinomas 
1 
2 
3 
4* 
5* 
colorectal tumors 
1 
2 
1 
2 
3 
cat 
1 
2 
3* 
4 
5 
6 
7* 
8 
9 
Canle 
Sheep 
*: actinic keratosis. Percentage of positive cells: O; +: less than 10% of cells; ++: 10 to 50% of cells; +++: more than 50% of cells. Staining intensity: 0; 
+: low; ++: mild; +++: moderate; ++++: marked; +++++: intense. 
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Flg. 4. Canine 
osteosarcoma (CM-1 
antibody). lntense 
nuclear staining was 
0bSe~ed in the 
rnajority of neoplasüc 
cell nuclei. x 200 
Fig. 5. Bovine 
squarnous cell 
carcinoma (CM-1 
antibody). Cords 
neoplastic cells 
rnarkedly stained 
scirrhous stroma. 
within 
x 100 
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al., 1996) and probably in animal tumors (Wolf et al., 
1997; Vitellozzi et al., 1998). This staining pattern could 
be specific for p53 presence in cytoplasm, since severa1 
mechanisms of cytoplasmic p53 sequestration and 
inactivation have been described, such as interactions 
with vira1 or cellular proteins (mdm2, bc12, hsp 70) 
(Finlay et al., 1988; Momand et al., 1992; Ryan et al., 
1994; Canman and Kastan, 1997) or nuclear transport 
dysregulation (eventually caused by some mutations) 
(Ozbun and Butel, 1997). Considering cytoplasmic 
staining as a positive result without nonspecific staining 
background evaluation, could be erroneous and lead to 
the overestimation of the role of p53 in tumorigenesis. 
Despite absence of labelling of normal tissue, and 
the obtained similar immunoreactivity pattern as 
observed in human tumors, it must be pointed out that 
further biochemical studies (such as Western blot) are 
needed to definitively characterize antibodies used. 
In contrast to other species tested here, SCC in dogs 
presented no p53 immunoreactivity in the few tumors 
tested. Previous studies also reported a low incidence or 
absence of p53 staining (Johnston et al., 1996; Gamblin 
et al., 1997; Teifke et al., 1998). These results suggest 
that p53 mutations are of less importance in SCC in the 
dog. However, p53 mutations should not be absolutely 
discarded because gene alterations (nonosense 
mutations, deletions or intronic mutations) leading to 
unstable mutant p53 proteins might explain these 
findings. Nevertheless it seems that SCC genesis 
mechanisms in dogs are not equivalent to other species. 
On the contrary, pronounced p53 immunoreactivity was 
obtained in feline SCC, as already reported in one study 
(Teifke and Lohr, 1996), and in human actinic keratosis. 
In cutaneous SCC, p53 alterations mostly are typically 
transversions (C:G F A )  due to UV radiations and would 
be early (Nelson et al., 1994; Coulter et al., 1995; Pi£Eko 
et al., 1995; Ananthaswamy et al., 1998) and common 
(Ogden et al., 1992; Caamano et al., 1993; Mao et al., 
1995) events in the tumor progression. Our results 
suggest that in cats, like in humans, p53 mutations may 
be involved early in the malignant conversion of actinic 
keratosis to SCC, a neoplasm well known to be UV- 
induced. In such lesions, p53 immunoreactivity could 
represent a useful biomarker for progression to 
malignancy. 
Correlation between p53 nuclear staining and gene 
mutation is highly significative in numerous human solid 
cancers (Baas et al., 1994; Martin, 1995). However, 
overexpression or accumulation of wild-type p53 protein 
can occur in a variety of situations, such as induction by 
normal cellular stimuli (DNA damage, apoptosis) 
(Canman and Kastan, 1997), or protein binding that 
leads to alterations of p53 degradation pathways. 
Furthermore, although PAb-240 antibody recognizes a 
conformational mutant p53, positive staining associated 
with this antibody does not necessarily means that gene 
mutation occurred; for example, unmasking methods 
could result in conformational changes of the protein, 
Flg. 6. Equine 
squamous cell 
carcinoma (CM-1 
antibody). lntense 
nuclear staining in the 
majorlty of tumor ceils. 
x 100 
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which could enable antibody recognition. Thus, the 
staining extent (number of positive cells) is the primary 
point of consideration. If this latter is superior to 10% , it 
suggests gene alteration, because wild-type p53 
accumulation remains a transient phenomenon that 
affects only few cells simultaneously. Positive immuno- 
reactivity due to gene alterations andlor loss of p53 
function would likely be an essential and irreversible 
step in tumorigenesis. 
This study shows that it is possible to evaluate p53 
immunoreactivity in many domestic species. Molecular 
techniques aiming to assess genetic alterations with 
more accuracy, determination of p53 overexpression 
prevalence in various tumors and the eventual prognostic 
significance, remain to be completed. Before such 
prognostic relevante can be placed on these rnarkers, it 
is first necessary to standardize methodologies (choice of 
antibody and experimental conditions: dilutions, antigen 
retrieval technique, negative controls, fixation times) and 
to define positivity thresholds, in order to appreciate the 
role of p53 in spontaneous neoplasms in veterinary 
patients. 
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